Orazio Fortunato, PhD: Tumor Genomic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
Orazio Fortunato, PhD, Tumor Genomic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Due to his expertise in biomarkers, he is involved directly in the development and analyses of circulating extracellular vesicles as biomarkers in plasma of lung cancer patients. He had given a major contribution to the study of miRNAs, particularly focusing on those miRNAs de-regulated in lung tumors and plasma samples. Recently, his research is focused on the functional role of extracellular vesicles in the development and progression of lung cancer. His current interest also includes the identification of extracellular vesicles as biomarkers of response to immunotherapy in cancer patients.
Irina Matei, PhD: Weill Cornell Medicine, USA
Irina Matei is an Assistant Professor of Immunology Research for Weill Cornell Medicine. She has expertise in cancer metastasis and exosome biology and combines innovative basic tumor biology research with translational studies, relating basic discoveries to advances in patient treatments. Her current research focuses on the crosstalk between tumor cells and the local and distant tumor microenvironment via exosomes. Specifically, she is interested in deciphering the role of exosomes in mediating the crosstalk within and with the immune system in normal physiology, cancer and autoimmunity. Dr. Matei’s current work is focused on the mechanisms through which exosomes coax the immune system to contribute to malignant progression.
Chunlin Ou, PhD: Xiangya Hospital, Central South University, China

Chunlin Ou is a Professor for Xiangya Hospital, Central South University, working for the department of Pathology. His researches focus on the molecular targeted therapy for human cancers, which mainly involve: the role of Hippo/YAP signaling pathway in targeted therapy of cancers; exploring the regulatory mechanism of extracellular vesicles-derived non-coding RNAs in cancers; searching novel biomarkers and drug targets for the early diagnosis and therapy of cancers; and clinical application of mRNA vaccine in cancers. Professor Ou is also an Editorial Board member of BMC Cancer.
This Collection welcomes submission of research articles, data notes, study protocols, and database articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, SNAPP. During the submission process you will be asked whether you are submitting to a Collection, please select "Extracellular vesicles in cancer progression" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.